Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8522763 | 1.00 | MEN1 (0.62) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL15259238 | 0.89 | MEN1 (0.62) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL12872270 | 0.89 | MEN1 (0.62) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL15374789 | 0.88 | MEN1 (0.61) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL125997 | 0.88 | MEN1 (0.61) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL15986522 | 0.87 | MEN1 (0.57) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL12708803 | 0.85 | MEN1 (0.58) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL13887892 | 0.84 | MEN1 (0.57) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL9911975 | 0.84 | MEN1 (0.56) | MEN1LMNACYP3A4KMT2ANEU1 | |
| SCHEMBL28589327 | 0.84 | MEN1 (0.57) | MEN1LMNACYP3A4KMT2ANEU1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1059283-B1 | Process for preparing neuraminidase inhibitor ro-64-0796 | HOFFMANN LA ROCHE (CH) | 2003-05-28 | — | — | EP | claimed |
| US-20020095040-A1 | Process for preparing 1,2-diamino compounds | KARPF MARTIN (CH) | 2002-07-18 | — | — | US | claimed |
| EP-1059283-A1 | Process for preparing neuraminidase inhibitor ro-64-0796 | F. HOFFMANN-LA ROCHE AG (CH) | 2000-12-13 | — | — | EP | claimed |
| US-9150498-B2 | Process for the preparation of oseltamivir and methyl 3-epi-shikimate | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-10-06 | — | — | US | disclosed |
| US-9150498-B2 | Process for the preparation of oseltamivir and methyl 3-epi-shikimate | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-10-06 | — | — | US | disclosed |
| US-20140243537-A1 | PROCESS FOR THE PREPARATION OF OSELTAMIVIR AND METHYL 3-EPI-SHIKIMATE | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-08-28 | — | — | US | disclosed |
| US-20140243537-A1 | PROCESS FOR THE PREPARATION OF OSELTAMIVIR AND METHYL 3-EPI-SHIKIMATE | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-08-28 | — | — | US | disclosed |
| US-8524940-B2 | Nitro group-containing ether compound and method for producing same | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8524940-B2 | Nitro group-containing ether compound and method for producing same | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20120130092-A1 | NITRO GROUP-CONTAINING ETHER COMPOUND AND METHOD FOR PRODUCING SAME | NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY (JP) | 2012-05-24 | — | — | US | disclosed |
| EP-1791808-B1 | PROCESS FOR THE PREPARATION OF 4,5-DIAMINO SHIKIMICACID | HOFFMANN LA ROCHE (CH) | 2010-07-14 | — | — | EP | disclosed |
| US-7514580-B2 | Process for the preparation of 4,5-diamino shikimic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1791808-A1 | PROCESS FOR THE PREPARATION OF 4,5-DIAMINO SHIKIMICACID | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006024436-A1 | PROCESS FOR THE PREPARATION OF 4,5-DIAMINO SHIKIMICACID | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-09 | — | — | WO | disclosed |
| US-20060047002-A1 | Process for the preparation of 4,5-diamino shikimic acid derivatives | HOFFMANN-LA ROCHE INC. | 2006-03-02 | — | — | US | disclosed |
| US-6939986-B2 | Process for preparing 1,2-diamino compounds | HOFFMANN-LA ROCHE INC. (US) | 2005-09-06 | — | — | US | disclosed |
| EP-1059283-B1 | Process for preparing neuraminidase inhibitor ro-64-0796 | HOFFMANN LA ROCHE (CH) | 2003-05-28 | — | — | EP | disclosed |
| US-6437171-B1 | AZIDE-FREE; PREPARING 2-AMINOALCOHOLS FROM 1,2-EPOXIDES AND AN AMINE; PROTECTING THE FREE AMINO GROUP, HYDROXY LEAVING GROUP, DEPROTECTING, REACTING WITH AN AMINE, ACYLATING, DEPROTECTING | HOFFMAN-LA ROCHE INC. | 2002-08-20 | — | — | US | disclosed |
| US-20020095040-A1 | Process for preparing 1,2-diamino compounds | KARPF MARTIN (CH) | 2002-07-18 | — | — | US | disclosed |
| EP-1059283-A1 | Process for preparing neuraminidase inhibitor ro-64-0796 | F. HOFFMANN-LA ROCHE AG (CH) | 2000-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243537-A1 | PROCESS FOR THE PREPARATION OF OSELTAMIVIR AND METHYL 3-EPI-SHIKIMATE | CYP51A1, CYP2B6, CYP2C8 | MEN1 4095/4885LMNA 4533/4885CYP3A4 14/4885 |
| US-20020095040-A1 | Process for preparing 1,2-diamino compounds | AOC1, UGT1A1, THPO | MEN1 375/4885LMNA 2657/4885CYP3A4 44/4885 |
| US-20060047002-A1 | Process for the preparation of 4,5-diamino shikimic acid derivatives | NEU4, NEU1, NEU3 | MEN1 3031/4885LMNA 2678/4885CYP3A4 209/4885 |
| US-20120130092-A1 | NITRO GROUP-CONTAINING ETHER COMPOUND AND METHOD FOR PRODUCING SAME | G6PD, TALDO1, DERA | MEN1 3456/4885LMNA 3882/4885CYP3A4 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.